Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System.

Abstract

Parkinson's disease is a common progressive neurodegenerative disorder presenting with characteristic motor symptoms. Non-motor dysfunctions and therapyrelated complications frequently develop, but are often underdiagnosed and undertreated. Levodopa- induced dyskinesia and impulse control disorders are suggested to share pathophysiological processes and m a y be related to alterations of the glutamatergic neurotransmission. Anti- glutamatergic interventions are therefore worth considering: several lines of evidence already indicate their beneficial effect. The kynurenine pathway offers the endogenous glutamate receptor antagonist kynurenic acid, which may act as a promising candidate for future drug development with the aim of assessment of the motor symptoms and therapy-related complications of Parkinson's disease.

• Authors: Zsófia Majláth, József Toldi, Ferenc Fülöp, László Vécsei
• Journal: Current medicinal chemistry (Curr Med Chem) Vol. 23 Issue 9 Pg. 874-83 ( 2016) ISSN: 1875-533X [Electronic] United Arab Emirates
• PMID: 26872942 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antiparkinson Agents
• Dopamine Agents
• Kynurenine
• Levodopa

Topics

• Animals
• Antiparkinson Agents (adverse effects, therapeutic use)
• Dopamine Agents (metabolism)
• Dyskinesia, Drug-Induced (complications, drug therapy, metabolism)
• Humans
• Kynurenine (metabolism)
• Levodopa (adverse effects, therapeutic use)
• Molecular Structure
• Parkinson Disease (complications, drug therapy, metabolism)